Computer-Aided Discovery of New Fgfr-1 Inhibitors Followed by In Vitro Validation

References

• Hanahan D , WeinbergRA. The hallmarks of cancer. Cell100 (1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Pietras K , ÖstmanA. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell. Res.316 (8), 1324–1331 (2010).
   PubMed Web of Science ®Google Scholar
• Haugsten EM , WiedlochaA, OlsnesS, WescheJ. Roles of fibroblast growth factor receptors in carcinogenesis. Mol. Cancer Biol.8 (11), 1439–1452 (2010).
   Google Scholar
• Wesche J , HaglundK, HaugstenEM. Fibroblast growth factors and their receptors in cancer. Biochem. J.437 (2), 199–213 (2011).
   PubMed Web of Science ®Google Scholar
• Ahmad I , IwataT, LeungHY. Mechanisms of FGFR-mediated carcinogenesis. Biochim. Biophys. Acta1823 (4), 850–860 (2012).
   PubMed Web of Science ®Google Scholar
• Beenken A , MohammadiM. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov.8 (3), 235–253 (2009).
   PubMed Web of Science ®Google Scholar
• Raju R , PalapettaSM, SandhyaVKet al. A network map of FGF-1/FGFR signaling system. J. Signal Transduct.2014, 962962 (2014).
   PubMedGoogle Scholar
• Ruge E , KortingH, BorelliC. Current state of three-dimensional characterisation of antifungal targets and its use for molecular modelling in drug design. Int. J. Antimicrob. Agents26 (6), 427–441 (2005).
   PubMed Web of Science ®Google Scholar
• Kapetanovic I . Computer-aided drug discovery and development (CADDD): in silico–chemico–biological approach. Chem. Biol. Interact.171 (2), 165–176 (2008).
   PubMed Web of Science ®Google Scholar
• Song CM , LimSJ, TongJC. Recent advances in computer-aided drug design. Brief. Bioinform.10 (5), 579–591 (2009).
   PubMed Web of Science ®Google Scholar
• Abu Hammad AM , TahaMO. Pharmacophore modeling, quantitative structure–activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors. J. Chem. Inf. Model.49 (4), 978–996 (2009).
   PubMed Web of Science ®Google Scholar
• Abuhamdah S , HabashM, TahaMO. Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors. J. Comput. Aided Mol. Des.27 (12), 1075–1092 (2013).
   PubMed Web of Science ®Google Scholar
• Al-Masri IM , MohammadMK, TahaMO. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening. ChemMedChem3 (11), 1763–1779 (2008).
   PubMed Web of Science ®Google Scholar
• Al-Nadaf A , SheikhaGA, TahaMO. Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent β-secretase inhibitory leads. Bioorg. Med. Chem.18 (9), 3088–3115 (2010).
   PubMed Web of Science ®Google Scholar
• Al-Nadaf A , TahaMO. Ligand-based pharmacophore exploration and QSAR analysis of transition state analogues followed by in silico screening guide the discovery of new sub-micromolar β-secreatase inhibitors. Med. Chem. Res.22 (4), 1979–1997 (2013).
   Web of Science ®Google Scholar
• Al-Sha'er MA , KhanfarMA, TahaMO. Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis. J. Mol. Model.20 (1), 1–15 (2014).
   Web of Science ®Google Scholar
• Al-Sha'er MA , TahaMO. Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors. J. Chem. Inf. Model.50 (9), 1706–1723 (2010).
   PubMed Web of Science ®Google Scholar
• Khanfar MA , TahaMO. Elaborate ligand-based modeling coupled with multiple linear regression and k nearest neighbor QSAR analyses unveiled new nanomolar mTOR inhibitors. J. Chem. Inf. Model.53 (10), 2587–2612 (2013).
   PubMed Web of Science ®Google Scholar
• Taha MO . Mixing pharmacophore modeling and classical QSAR analysis as powerful tool for lead discovery. In : Virtual Screening. TahaMO ( Ed.). InTech, Rijeka, Croatia, 1 (2012). http://cdn.intechopen.com/pdfs/32264.pdf.
   Google Scholar
• Taha MO , AtallahN, Al-BakriAGet al. Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening. Bioorg. Med. Chem.16 (3), 1218–1235 (2008).
   PubMed Web of Science ®Google Scholar
• Taha MO , BustanjiY, Al-BakriAGet al. Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening. J. Mol. Graph. Model.25 (6), 870–884 (2007).
   PubMed Web of Science ®Google Scholar
• Taha MO , QandilAM, Al-HaraznahT, KhalafRA, ZalloumH, Al-BakriAG. Discovery of new antifungal leads via pharmacophore modeling and QSAR analysis of fungal N-myristoyl transferase inhibitors followed by in silico screening. Chem. Biol. Drug. Des.78 (3), 391–407 (2011).
   PubMed Web of Science ®Google Scholar
• Al-Sha'er MA , TahaMO. Application of docking-based comparative intermolecular contacts analysis to validate Hsp90α docking studies and subsequent in silico screening for inhibitors. J. Mol. Model.18 (11), 4843–4863 (2012).
   PubMed Web of Science ®Google Scholar
• Taha MO , HabashM, Al-HadidiZ, Al-BakriA, YounisK, SisanS. Docking-based comparative intermolecular contacts analysis as new 3-D QSAR concept for validating docking studies and in silico screening: NMT and GP inhibitors as case studies. J. Chem. Inf. Model.51 (3), 647–669 (2011).
   PubMed Web of Science ®Google Scholar
• Taha MO , HabashM, KhanfarMA. The use of docking-based comparative intermolecular contacts analysis to identify optimal docking conditions within glucokinase and to discover of new GK activators. J. Comput. Aided Mol. Des.28 (5), 509–547 (2014).
   PubMed Web of Science ®Google Scholar
• Jaradat NJ , KhanfarMA, HabashM, TahaMO. Combining docking-based comparative intermolecular contacts analysis and k-nearest neighbor correlation for the discovery of new check point kinase 1 inhibitors. J. Comput. Aided Mol. Des.29 (6), 561–581 (2015).
   PubMed Web of Science ®Google Scholar
• Waszkowycz B . Structure-based approaches to drug design and virtual screening. Curr. Opin. Drug Discov. Devel.5 (3), 407–413 (2002).
   PubMedGoogle Scholar
• Zhou N , XuY, LiuXet al. Combinatorial pharmacophore-based 3D-QSAR analysis and virtual screening of FGFR1 inhibitors. Int. J. Mol. Sci.16 (6), 13407–13426 (2015).
   PubMed Web of Science ®Google Scholar
• Suneel Kumar B , LakshmiN, Ravi KumarMet al. Design, synthesis and screening studies of potent thiazol-2-amine derivatives as fibroblast growth factor receptor 1 inhibitors. Curr. Top. Med. Chem.14 (17), 2031–2041 (2014).
   PubMed Web of Science ®Google Scholar
• Ravindranathan KP , MandiyanV, EkkatiAR, BaeJH, SchlessingerJ, JorgensenWL. Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening. J. Med. Chem.53 (4), 1662–1672 (2010).
   PubMed Web of Science ®Google Scholar
• Gryshchenko A , BdzholaV, BalandaAet al. Design, synthesis and biological evaluation of N-phenylthieno [2, 3-d] pyrimidin-4-amines as inhibitors of FGFR1. Bioorg. Med. Chem.23 (9), 2287–2293 (2015).
   PubMed Web of Science ®Google Scholar
• Gryshchenko A , TarnavskiyS, LevchenkoKet al. Design, synthesis and biological evaluation of 5-amino-4-(1H-benzoimidazol-2-yl)-phenyl-1, 2-dihydro-pyrrol-3-ones as inhibitors of protein kinase FGFR1. Bioorg. Med. Chem.24 (9), 2053–2059 (2016).
   PubMed Web of Science ®Google Scholar
• Taha MO , Al-BakriAG, ZalloumWA. Discovery of potent inhibitors of pseudomonal quorum sensing via pharmacophore modeling and in silico screening. Bioorg. Med. Chem. Lett.16 (22), 5902–5906 (2006).
   PubMed Web of Science ®Google Scholar
• Taha MO , BustanjiY, Al-GhusseinMAet al. Pharmacophore modeling, quantitative structure–activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3β inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin. J. Med. Chem.51 (7), 2062–2077 (2008).
   PubMed Web of Science ®Google Scholar
• Taha MO , DahabiyehLA, BustanjiY, ZalloumH, SalehS. Combining ligand-based pharmacophore modeling, quantitative structure–activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors. J. Med. Chem.51 (20), 6478–6494 (2008).
   PubMed Web of Science ®Google Scholar
• Guide CU . Accelrys Software, Inc., CA, USA (2005).
   Google Scholar
• Biovea . www.biovea.com.
   Google Scholar
• CamebridgeSoft . www.cambridgesoft.com.
   Google Scholar
• MathWorks . www.mathworks.com.
   Google Scholar
• Borzilleri RM , ZhengX, QianLet al. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl) phenylamino) pyrrolo [2,1-f][1, 2, 4] triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. J. Med. Chem.48 (12), 3991–4008 (2005).
   PubMed Web of Science ®Google Scholar
• Sun L , TranN, LiangCet al. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl) methylidenyl] indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J. Med. Chem.42 (25), 5120–5130 (1999).
   PubMed Web of Science ®Google Scholar
• Sun L , TranN, LiangCet al. Identification of substituted 3-[(4, 5, 6, 7-tetrahydro-1 H-indol-2-yl) methylene]-1, 3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ tyrosine kinases. J. Med. Chem.43 (14), 2655–2663 (2000).
   PubMed Web of Science ®Google Scholar
• Smellie A , KahnSD, TeigSL. Analysis of conformational coverage. 1. Validation and estimation of coverage. J. Chem. Inform. Comput. Sci.35 (2), 285–294 (1995).
   Google Scholar
• Hahn M . Three-dimensional shape-based searching of conformationally flexible compounds. J. Chem. Inform. Comput. Sci.37 (1), 80–86 (1997).
   Google Scholar
• Guner O , ClementO, KurogiY. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst: recent advances. Curr. Med. Chem.11 (22), 2991–3005 (2004).
   PubMed Web of Science ®Google Scholar
• Krovat EM , LangerT. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J. Med. Chem.46 (5), 716–726 (2003).
   PubMed Web of Science ®Google Scholar
• Kurogi Y , GunerOF. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem.8 (9), 1035–1055 (2001).
   PubMed Web of Science ®Google Scholar
• Leach AR , GilletVJ, LewisRA, TaylorR. Three-dimensional pharmacophore methods in drug discovery. J. Med. Chem53 (2), 539–558 (2010).
   PubMed Web of Science ®Google Scholar
• Poptodorov K , LuuT, HoffmannRD. Pharmacophore model generation software tools. In : Methods and Principles in Medicinal Chemistry. Pharmacophores and Pharmacophore Searches Vol. 32. LangerT, HoffmannRD ( Eds). Wiley-VCH, Weinheim, Germany, 17 (2006).
   Google Scholar
• Rogers D , HopfingerAJ. Application of genetic function approximation to quantitative structure–activity relationships and quantitative structure–property relationships. J. Chem. Inform. Comput. Sci.34 (4), 854–866 (1994).
   Google Scholar
• Zheng W , TropshaA. Novel variable selection quantitative structure–property relationship approach based on the k-nearest-neighbor principle. J. Chem. Inform. Comput. Sci.40 (1), 185–194 (2000).
   PubMedGoogle Scholar
• Gasteiger J , MarsiliM. Iterative partial equalization of orbital electronegativity – a rapid access to atomic charges. Tetrahedron36 (22), 3219–3228 (1980).
   Web of Science ®Google Scholar
• Diller DJ , MerzKM. High throughput docking for library design and library prioritization. Proteins43 (2), 113–124 (2001).
   PubMed Web of Science ®Google Scholar
• Rao SN , HeadMS, KulkarniA, LalondeJM. Validation studies of the site-directed docking program LibDock. J. Chem. Inf. Model.47 (6), 2159–2171 (2007).
   PubMed Web of Science ®Google Scholar
• Jain AN . Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities. J. Comput. Aided Mol. Des.10 (5), 427–440 (1996).
   PubMed Web of Science ®Google Scholar
• Venkatachalam CM , JiangX, OldfieldT, WaldmanM. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J. Mol. Graph. Model.21 (4), 289–307 (2003).
   PubMed Web of Science ®Google Scholar
• Gehlhaar DK , BouzidaD, RejtoPA. Reduced dimensionality in ligand–protein structure prediction: covalent inhibitors of serine proteases and design of site-directed combinatorial libraries. In : ACS Symposium Series. American Chemical Society, 292–311 (1999).
   Google Scholar
• Muegge I . A knowledge-based scoring function for protein–ligand interactions: probing the reference state. In : Virtual Screening: An Alternative or Complement to High Throughput Screening?KlebeG ( Ed.). Kluwer Academic Publishers, The Netherlands, 99–114 (2002).
   Google Scholar
• Muegge I , MartinYC. A general and fast scoring function for protein–ligand interactions: a simplified potential approach. J. Med. Chem.42 (5), 791–804 (1999).
   PubMed Web of Science ®Google Scholar
• Triballeau N , AcherF, BrabetI, PinJP, BertrandHO. Virtual screening workflow development guided by the ‘receiver operating characteristic’ curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J. Med. Chem.48 (7), 2534–2547 (2005).
   PubMed Web of Science ®Google Scholar
• Verdonk ML , BerdiniV, HartshornMJet al. Virtual screening using protein–ligand docking: avoiding artificial enrichment. J. Chem. Inform. Comput. Sci.44 (3), 793–806 (2004).
   PubMedGoogle Scholar
• Kirchmair J , MarktP, DistintoS, WolberG, LangerT. Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection – what can we learn from earlier mistakes?J. Comput. Aided Mol. Des.22 (3–4), 213–228 (2008).
   PubMed Web of Science ®Google Scholar
• Lipinski CA , LombardoF, DominyBW, FeeneyPJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev.64, 4–17 (2012).
   Web of Science ®Google Scholar
• Veber DF , JohnsonSR, ChengHY, SmithBR, WardKW, KoppleKD. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem.45 (12), 2615–2623 (2002).
   PubMed Web of Science ®Google Scholar
• Khalaf RA , AbdulaAM, MubarakMS, TahaMO. Discovery of new β-D-glucosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening. J. Mol. Model.17 (3), 443–464 (2011).
   PubMed Web of Science ®Google Scholar
• Sprague PW , HoffmannR. CATALYST pharmacophore models and their utility as queries for searching 3D databases. In : Computer-Assisted Lead Finding and Optimization: Current Tools for Medicinal Chemistry. van de WaterbeemdH, TestaB, FolkersG ( Eds). Wiley-VCH, Weinheim, Germany, 223–240 (1997).
   Google Scholar
• Taha MO , TarairahM, ZalloumH, Abu-SheikhaG. Pharmacophore and QSAR modeling of estrogen receptor β ligands and subsequent validation and in silico search for new hits. J. Mol. Graph. Model.28 (5), 383–400 (2010).
   PubMed Web of Science ®Google Scholar
• Bello E , ColellaG, ScarlatoVet al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res.71 (4), 1396–1405 (2011).
   PubMed Web of Science ®Google Scholar
• Nakanishi Y , AkiyamaN, TsukaguchiTet al. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol. Cancer Ther.13 (11), 2547–2558 (2014).
   PubMed Web of Science ®Google Scholar
• Abuhammad A , TahaMO. QSAR studies in the discovery of novel type-II diabetic therapies. Expert Opin. Drug Discov.11 (2), 197–214 (2016).
   PubMed Web of Science ®Google Scholar
• Buchwald P , BodorN. Computer-aided drug design: the role of quantitative structure–property, structure–activity and structure–metabolism relationships (QSPR, QSAR, QSMR). Drug Future27 (6), 577–588 (2002).
   Web of Science ®Google Scholar
• Cronin MT , SchultzTW. Pitfalls in QSAR. Comp. Theor. Chem.622 (1), 39–51 (2003).
   Google Scholar
• Abuhammad A , TahaM. Innovative computer-aided methods for the discovery of new kinase ligands. Future Med. Chem.8 (5), 509–526 (2016).
   PubMed Web of Science ®Google Scholar
• Shoichet BK . Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem.49 (25), 7274–7277 (2006).
   PubMed Web of Science ®Google Scholar
• Walters WP , NamchukM. Designing screens: how to make your hits a hit. Nat. Rev. Drug Discov.2 (4), 259–266 (2003).
   PubMed Web of Science ®Google Scholar